PentixaPharm
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bismarckstraße 13, Wuerzburg, Bavaria, 9...Phone Number
+49 93199136076Website
www.pentixapharm.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About PentixaPharm
Pentixapharm is a radiopharmaceutical development company based in Würzburg, Germany, founded in 2019. The company focuses on developing innovative theranostic pairs, specifically PentixaFor and PentixaTher, which target the CXCR4-receptor. With a strong emphasis on research and development, Pentixapharm has administered compounds to over 2,000 patients and has two Phase-III-ready drug candidates. Their intended clients include healthcare providers and researchers in the field of oncology and related medical disciplines.Explore more
PentixaPharm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PentixaPharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if PentixaPharm is spiking on competitors!
Click to see if PentixaPharm had a recent Job posting/layoffs
Earning: See what the market has to say on PentixaPharm recently announced quarterly report
Funding: Get notified immidiatlly once PentixaPharm has new funding data
Congratulate Masked Content for being promoted to Masked Content at PentixaPharm
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if PentixaPharm has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PentixaPharm launches new products
PentixaPharm, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at PentixaPharm
Find 3 more new buyers
Company Profile Activity
Activity Insights
PentixaPharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PentixaPharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PentixaPharm.
PentixaPharm Tech Stack
A closer look at the technologies used by PentixaPharm
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Partnership
Partnership, Logistics / Supply Chain, Manufacturing Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move
PentixaPharm News & Media
Eckert & Ziegler signs manufacturing deal with Pentixapharm - AuntMinnie
Eckert & Ziegler Radiopharma GmbH has signed a manufacturing agreement with Pentixapharm.Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
BERLIN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies. The transaction, which will be effective still in 2024, involves rights that had been transferred to Pentixapharm as part of the acquisition of Glycotope’s target discovery business in July 2024.First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical trial evaluating the safety and efficacy of Lu177-PentixaTher, a novel radiopharmaceutical therapy, in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The trial, funded by thePentixapharm Releases Interim Report for the Third Quarter of 2024 - PharmiWeb.com
EQS-News: Pentixapharm Holding AG / Key word(s): Quarterly / Interim StatementPentixapharm Releases Interim Report for the Third Quarter of 2024 12.11.2024 / 17:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PentixaPharm
Sign Up For FreeTo access detailed company insights
Pentixapharm is a radiopharmaceutical development company based in Würzburg, Germany, founded in 2019. The company focuses on developing innovative theranostic pairs, specifically PentixaFor and PentixaTher, which target the CXCR4-receptor. With a strong emphasis on research and development, Pentixapharm has administered compounds to over 2,000 pat... Read More
